EVAPORATE: high-dose EPA reversed plaque in patients with triglycerides above 135 mg/dL
Louis summarizes the EVAPORATE randomized trial, where purified EPA (icosapent ethyl) shrank coronary plaque in patients with elevated triglycerides, and warns high doses can increase AFib.
